{
    "clinical_study": {
        "@rank": "122561", 
        "acronym": "X-ACT", 
        "arm_group": [
            {
                "arm_group_label": "1 Omalizumab", 
                "arm_group_type": "Experimental", 
                "description": "omalizumab once a month via subcutaneous injection."
            }, 
            {
                "arm_group_label": "2 Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo of omalizumab once a month via subcutaneous injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the impact of omalizumab on the quality of life improvement when\n      added to the standard therapy in refractory patients suffering from chronic spontaneous\n      urticaria and angioedema."
        }, 
        "brief_title": "Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Spontaneous Urticaria", 
            "Angioedema"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Angioedema", 
                "Urticaria"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be conducted using a double-blind, placebo-controlled, randomized,\n      multicenter design to investigate the impact of omalizumab on Quality of Life (QoL) in\n      Chronic Spontaneous Urticaria (CSU) and will assess its effectiveness in reducing and/or\n      inhibiting the occurrence, time-course and severity of angioedema episodes.\n\n      Omalizumab is administered subcutaneously every 4 weeks as an add-on therapy to the current\n      approved treatment of adult CSU patients. The treatment period is 28 weeks which is followed\n      by an 8-week follow-up. The study aims to enroll approximately 70 patients.\n\n      The study is divided into a 2-week screening period, a 28-week double-blind treatment phase\n      with omalizumab or placebo-omalizumab, and an 8-week follow-up phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of chronic spontaneous urticaria (CSU) refractory to H1-antihistamine\n             treatment\n\n          -  Presence of itch an hives for more than 6 weeks\n\n          -  UAS7 score of more than 14 (range 0-42)\n\n          -  Patient has history of insufficient response to 4x of the approved dose of\n             H1-antihistamines\n\n          -  CSU diagnosis for more than 6 months\n\n          -  Angioedema at least 4x in the last 6 months\n\n        Exclusion Criteria:\n\n          -  Patients with non urticaria associated angioedema\n\n          -  History of hypersensitivity to omalizumab or the rescue medication or to drugs of\n             similar chemical structure\n\n          -  Evidence of parasitic infection\n\n          -  Previous treatment with omalizumab within the last 6 months prior to screening\n\n          -  History of anaphylactic shock\n\n          -  Woman who are pregnant or breast feeding\n\n          -  Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "91", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723072", 
            "org_study_id": "CIGE025EDE16"
        }, 
        "intervention": [
            {
                "arm_group_label": "1 Omalizumab", 
                "description": "Humanized monoclonal antibody against human IgE", 
                "intervention_name": "Omalizumab", 
                "intervention_type": "Biological", 
                "other_name": "IGE025"
            }, 
            {
                "arm_group_label": "2 Placebo", 
                "description": "Placebo to omalizumab", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo for Omalizumab"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Omalizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Chronic spontanous urticaria, refractory CSU, Angioedema", 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aachen", 
                        "country": "Germany", 
                        "zip": "52074"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augsburg", 
                        "country": "Germany", 
                        "zip": "86156"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10098"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bochum", 
                        "country": "Germany", 
                        "zip": "44791"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "53105"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Darmstadt", 
                        "country": "Germany", 
                        "zip": "64283"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany", 
                        "zip": "40225"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "zip": "91052"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45147"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "zip": "79106"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gera", 
                        "country": "Germany", 
                        "zip": "07548"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halle/Saale", 
                        "country": "Germany", 
                        "zip": "06120"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "30625"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Homburg", 
                        "country": "Germany", 
                        "zip": "66421"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany", 
                        "zip": "24105"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "50924"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany", 
                        "zip": "68167"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany", 
                        "zip": "80336"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "zip": "81675"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oldenburg", 
                        "country": "Germany", 
                        "zip": "26133"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Regensburg", 
                        "country": "Germany", 
                        "zip": "93053"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Selters", 
                        "country": "Germany", 
                        "zip": "56242"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiesbaden", 
                        "country": "Germany", 
                        "zip": "64191"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy.", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The CU-Q2oL is a questionnaire that measures the relative burden of chronic urticaria on subjective well-being. It consists of 23 questions in 3 domains (symptoms, general impairment, difficulties and problems due to urticaria). Patients are asked to respond how much they are troubled by each problem on a 5-point Likert scale (1= not at all to 5= very much). An overall score is calculated and normalized to a scale of 1 to 100.", 
            "measure": "Chronic urticaria quality of life questionnaire (CU-Q2oL)", 
            "safety_issue": "No", 
            "time_frame": "Baseline/week 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723072"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The AE-Q2oL is a questionnaire for patients suffering from angioedema. It consists of 29 questions relevant to angioedema and its specific impact on quality of life. Patients are asked to respond how much they are troubled be each problem on a 5-point Likert scale (1= does not apply to 5= very much). An overall score is calculated and a higher score indicates lower quality of life. A negative change score (week 28 score minus baseline score) indicates improvement.", 
                "measure": "Angioedema Quality of Life Score (AE-Q2oL)", 
                "safety_issue": "No", 
                "time_frame": "Baseline/week 28"
            }, 
            {
                "description": "A cumulative activity score, evaluated in the screening period and throughout the study. The  records each evening on a daily basis symptoms of itch and hives into a patient diary. The UAS is a composite score with numeric severity intensity ratings on a scale of 0 - 3 for the number of wheals (hives) and the itch intensity. The UAS7 is the sum of the daily UAS scores over 7 days.", 
                "measure": "Weekly Urticaria Score (UAS7)", 
                "safety_issue": "No", 
                "time_frame": "Baseline/week 28"
            }, 
            {
                "description": "The intake of sedating anti-histamines as well as the use of corticosteroids will be measured on a daily basis throughout the study and summarized descriptively. The amount and rate of required rescue medication will be summarized and compared inferentially between treatment groups.", 
                "measure": "Use of rescue medication", 
                "safety_issue": "No", 
                "time_frame": "Baseline/week 28"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}